Scientists have identified a little-known protein called Miro1 as a potentially significant contributor to insulin resistance in Type 2 diabetes, according to preclinical research. The findings suggest that an accumulation of Miro1 may impair the ability of muscle cells to respond to insulin, a hallmark of the disease. In laboratory experiments, removing the protein restored the muscles’ sensitivity to insulin, pointing to a previously unrecognized mechanism underlying metabolic dysfunction. The research adds to a growing body of work examining how cellular proteins influence glucose regulation and could inform future therapeutic strategies.
The study also found that exercise lowered Miro1 levels in people with diabetes, offering a possible explanation for the well-documented benefits of physical activity in managing the condition. Researchers say the discovery reveals a potential new pathway for treatment, though they caution that the work remains at the preclinical stage and requires further validation in human trials. If confirmed, targeting Miro1 could open avenues for interventions aimed at improving insulin sensitivity. The findings were reported in the context of broader efforts to understand why muscle tissue becomes resistant to insulin in Type 2 diabetes.
Independent reporting synthesized from primary wires and global correspondents.